Proteins of extracellular matrix undergo over time multiple reactions with glucose to form advanced glycosylation endproducts (AGEs) which are highly active in protein crosslinking, and have been implicated in tissue damage associated with aging and diabetes. A macrophage/monocyte receptor for AGE moieties mediates the uptake of AGE-modified proteins by a process that also induces cachectin/tumor necrosis factor (TNF) and IL-1 secretion. Reasoning that cytokines might regulate this AGE-receptor system, we have evaluated the effect of cachectin/TNF, IL-1, and IFN-y on AGE-protein processing. We report that cachectin/TNF induced a severalfold enhancement of binding, endocytosis, and degradation of AGE-BSA by both murine peritoneal macrophages and human blood monocytes in vitro, and that cachectin/TNF enhanced the rate of disappearance of AGE-modified red blood cells in vivo. IL-1 and IFN-'y alone did not increase AGE processing, but IFN--y consistently enhanced cachectin/TNF-induced changes in AGE-receptor kinetics. Similar effects were induced by AGE-BSA and FFI-BSA, a chemically synthesized AGE, when used as macrophage stimulants, possibly via cachectin/TNF induction. All upregulatory responses were blocked by anticachectin/TNF monoclonal antibody. These data suggest that AGE-induced cachectin/TNF, in addition to influencing tissue regeneration and remodelling, may also normally regulate the disposal of tissue damaging AGE-proteins through an autocrine upregulation.
Introduction
Glucose can react nonenzymatically with proteins to form, over time, stable covalent adducts called advanced glycosylation endproducts (AGEs),' which are characteristically fluorescent, yellow-brown pigments that can cross-link proteins and nucleic acids (1) (2) (3) . Accumulation of AGEs on long-lived proteins in vivo has been found to increase linearly with age and is accelerated in patients with diabetes (1, 4) .
We have previously demonstrated that macrophages possess a high affinity receptor that selectively recognizes proteins modified by AGEs (5) . AGE-modified proteins bind to macrophage receptors, become internalized, and are then degraded, with subsequent release oftheir component amino acids (5, 6 ). Scatchard analysis of AGE-BSA (bovine serum albumin, nonenzymatically glycosylated in vitro) binding to mouse peritoneal macrophages reveals 1 X IO' binding sites per cell with an affinity constant (Ka) of 1.75 X 107 M-1 (6) , functionally defining the AGE-receptor. A 90-kD protein, with AGE-binding affinity similar to the AGE-receptor has been purified to homogeneity from the cell membranes of the murine macrophage cell line RAW 264.7 (Radoff, S., and H. Vlassara. Submitted for publication.) (7) . In addition to taking up AGEmodified proteins, macrophages can recognize intact cells that have AGE chemically attached to their outer membrane, and AGE-modified RBC are removed from the circulation more rapidly than control cells (8) . Such studies suggest that accumulation of AGEs on the surface of long-lived cells could be responsible in part for the normal turnover oferythrocytes and endothelial cells, among others.
Binding of AGE-modified proteins to macrophages was recently found to stimulate synthesis and release oftwo potent monokines, cachectin/TNF and IL-1 (9) . The release of these factors with known growth-promoting activity may represent a mechanism by which macrophages signal to nearby cells to remove and replace senescent proteins.
Several macrophage receptors are known to be modulated by hormones and other physiological mediators (10, 11), therefore we have been testing for factors that participate in the regulation of AGE receptors. For example, previous studies have revealed that the number and affinity of AGE-receptors on macrophages are inversely correlated in vivo with insulin levels (12) , suggesting a regulatory role for insulin in this system. In the present communication we have evaluated the effects of various cytokines including IL-l, cachectin/TNF, and IFN-y on the expression and activity of AGE-receptors in murine and human macrophage/monocytes. These studies support the hypothesis that cachectin/TNF up-regulates AGE receptors on macrophages in vitro and in vivo, apparently via an autocrine regulatory mechanism.
Methods
Cell preparation. Resident peritoneal macrophages were harvested from mice (Balb/cJ; Jackson Laboratory, Bar Harbor, ME) in PBS as described previously (5, 6) . After total and differential cell counts, aliquots of 2 X 106 cells were seeded into 24-well culture dishes (Linbro, McLean, VA) and incubated at 37°C in 5% CO2 for 2 h, after which nonadherent cells were removed by rinsing with serum-free medium.
The buffy coat from 100 ml fresh human blood was diluted twofold with saline, pH 7.4, containing 1 mM EDTA. Mononuclear cells were first isolated by centrifugation over Ficoll-Hypaque gradients (8) , and were further purified by the Percoll gradient (13). Greater than 99% of the adhering cells were monocytes, as assessed by their ability to spread on surfaces ( 14) and ingest IgG-coated erythrocytes ( 15) . When ready for use, aliquots of 106 monocytes were suspended in RPMI 1640 (Gibco Laboratories, Grand Island, NY), plated into sterile Petri dishes, and incubated for 2 h at 370C in 5% Co2. Approximately 1.0 X 106 cells/well adhered routinely.
Preparation of AGE-modified proteins and AGE-BSA binding assays. AGE-BSA was prepared by incubating bovine serum albumin (BSA; Fraction V; Boehringer-Mannheim Biochemicals, Indianapolis, IN) in 10 mM PBS buffer, pH 7.4 with 50 mM glucose or glucose-6-phosphate at 370C for 6 wk, as described (6) . The amount of AGE formed on all BSA preparations was assessed by characteristic absorption and fluorescence spectra (16) and quantitated by radioimmunoassay (17) . FFI-BSA conjugate, a chemically synthesized AGE shown to be recognized by the AGE receptor (6) was made as previously described in detail ( 18) .
Binding studies of AGE-BSA were carried out under optimal conditions for each mediator or stimulant under study (see below), using either murine peritoneal macrophages or human blood monocytes, as described (6, 12) . AGE-BSA was radioiodinated with carrier-free 1251 (New England Nuclear Corp., Boston, MA) by the Iodogen method of Fraker and Speck (19) to a specific activity of -850 cpm/ng of protein. The amount of radiolabeled material specifically bound was subsequently determined and analyzed by Scatchard analysis (20) . Nonspecific binding was generally < 20% in these experiments. The intracellular accumulation and degradation of AGE-BSA were also measured as described previously (6) .
Cachectin/TNF binding assays. Recombinant human cachectin/ TNF (rhTNF; Chiron Corp., Emeryville, CA) was purified to > 99% electrophoretic homogeneity and radioiodinated by the lodogen method (19) . 10 gg of the purified protein was mixed with 5 mCi carrier-free 1251 (New England Nuclear) in 75 MAl of 50 mM Hepes buffer, pH 7.8, in an Iodogen-coated glass tube (Pierce Chemical Co., Rockford, IL) for 20 min at 4°C. The reactants were diluted to 2.5 ml with Hepes buffer containing 0.1% BSA and 0.5 M sodium iodide and passed through a Sephadex G-25 column (Pharmacia Fine Chemicals, Piscataway, NJ) equilibrated with 50 mM Hepes and 0.1% BSA. The labeled rhTNF which eluted in the void volume was dialyzed nine times against 1 liter 50 mM Hepes buffer, pH 7.8, containing 0.01% sodium azide. The specific activity of the '25I-rhTNF ranged from 6-9 X 109 cpm/mg protein; > 98% of the radioactivity was protein bound.
Thioglycolate-elicited macrophages from Balb/cJ mice and fresh normal human monocytes were prepared as described (6, 8, 13) , plated in 2 ml RPMI 1640 with 25% FBS and 0.1% gentamicin in similar 6-well plates (8 X polymyxin (100 ng-10 Mg/ml) was added to determine whether any of the responses reflected the presence of trace amounts of endotoxin not detectable by the Limulus assay. Cells were preincubated with various concentrations of rhTNF for periods of time between 2 h and 5 d, after which binding studies of radiolabeled AGE-BSA were performed to define the optimal preincubation conditions for maximal AGE-receptor expression. In some experiments, human monocytes were preincubated in media with 10% serum alone for 5 d, followed by 48 h of preincubation with rhTNF, when labeled ligand binding and degradation was tested. In addition, several 48-h preincubations were conducted in the presence of medium with 10% serum, rhTNF, and recombinant human IFN-y (1 ng/ml, 50 U/ml) (Amgen Biologicals, Thousand Oaks, CA).
AGE-BSA or FFI-BSA was added to the isolated macrophages or monocytes at different concentrations (Table II) , for 48 h at 370C.
Unmodified BSA that had been incubated in PBS alone for 6 wk was used as negative control. Cell monolayers were then washed three times with serum containing medium, after which binding for 2 h at 4VC, or uptake and degradation studies for 4 h at 370C were carried out as described (6 (23) . At the indicated times, the animals were bled (100 Ml) and the amount of radioactivity was determined.
Statistics. All data are expressed as means±SEM and were analyzed with one-way analysis of variance (24) .
Results
The binding, accumulation, and degradation of AGE-BSA by mouse macrophages that had been preincubated with cachectin/TNF, IL-I and IFN-y were assessed as described in Methods. As displayed in Fig. 1 the incubation of mouse macrophages with cachectin/TNF (20 ng/ml, 1 nM) for a 48-h period resulted in significant increases in the binding, accumutation, and degradation ofAGE-BSA. A twofold increase in labeled AGE-BSA specifically bound to macrophages preincu- bated with rhTNF was observed as compared with control cells (P < 0.005) ( Fig. 1 A) , accompanied by a fourfold increase in the amount accumulated intracellularly after incubation for 4 h at 37°C (P < 0.01) (Fig. 1 B) , and a twofold increase in the amount degraded by the cells preincubated with rhTNF (P < 0.005), measured as TCA soluble radioactivity in the medium ( Fig. 1 C) ; no significant change was observed in the binding and degradation of normal BSA. Under the same conditions, however, there was no significant effect of IL-1 or IFN-y on the binding, accumulation, or degradation of labeled AGE-BSA; although there was a considerable effect on the intracellular accumulation, and degradation of normal BSA by IL-1-treated macrophages, presumably via nonreceptor mediated pathways (Fig. 1) . Murine IFN-y added during the preincubation period either alone (Fig. 1 ) or in combination with cachectin/TNF (not shown) did not produce any remarkable effects on the binding, accumulation, or degradation of either ligand. No significant effects were observed at either higher or lower concentrations of IL-1 or IFN-,y (data not shown). The amount of cachectin/TNF found to optimally induce the effect was 20 ng/ml (1 nM); neither 0.1 nM nor 10 nM rhTNF had a statistically significant effect (Fig. 2) . When normal BSA was used as a ligand, only IL-1 elicited an increase 37°C. After washing away cachectin/TNF with serum containing media three times, media with 10% FCS was replaced and cellular uptake of labeled AGE-BSA for 4 h at 37°C was determined as described (6) . Data are expressed as the means±SEM of two independent experiments, each performed in triplicate. Amount of radiolabeled AGE-BSA added to the medium was 25 ug/ml.
in the amount accumulated and degraded compared to control cells (Fig. 1) . The time course of cachectin/TNF-mediated stimulation of radiolabeled AGE-BSA or normal BSA intracellular accumulation, representing the amount of radioactive ligand bound and taken-up minus the amount externalized after proteolytic digestion by murine macrophages is shown in Fig. 3 (Fig. 4, lower inset) . However, when freshly isolated human monocytes were preincubated with rhTNF for 48 h, saturated binding of 1251-AGE-BSA increased, reaching a maximum level more than twice as great as that reached in the absence of rhTNF (P < 0.005) (Fig. 4 , open circles). Scatchard plot analysis indicated a two-to threefold increase in both receptor number and binding affinity (Ka) compared to untreated cells (P < 0.01) (Fig. 4, upper (Table I) . A significant increase in binding affinity was also noted (P < 0.05), even though less pronounced. Intracellular accumulation of '25I-AGE-BSA also increased significantly in similar experiments during which freshly prepared human blood monocytes were preincubated with rhTNF in medium containing human -y-IFN (i ng/ml) added as a priming factor (25, 26) (Fig. 5) . Although these experiments were carried out in the presence of IFN-T, this agent alone did not enhance AGE-receptor activity (Fig. 5) , nor did it increase nonspecific endocytosis by these cells, as shown by the failure to influence normal albumin uptake and degradation. In the absence of IFN-'y, the cachectin/TNF effect was uniformly reduced to 60% of that observed in the presence of this cytokine (data not shown).
Since AGE-protein uptake by human peripheral monocytes has been shown to induce secretion of cachectin/TNF (9) , we reasoned that preincubation of monocytes with AGE-BSA or FFI-BSA at concentrations known to induce this monokine (250 and 150 ,Ag/ml, respectively, in the presence of IFN-y), should enhance AGE-BSA processing. As shown in (Fig. 5 A) . The amounts of labeled AGE-BSA degraded during these experiments followed a similar pattern: AGE-BSA or FFI-BSA pretreatment enhanced degradation of AGE-ligand (Fig. 5 B) . In contrast, AGE-BSA or FFI-BSA treatment had no effect on the accumulation or degradation of unmodified radiolabeled BSA.
A more than twofold increase in the amount of radiolabeled AGE-protein specifically bound at 4°C by cells pretreated with cachectin/TNF, and FFI-BSA was also noted ( Amount of radioligand added to the medium was 25 jog/ml. Table II , AGE-receptor binding increased in response to increasing AGE-modified protein concentration up to 250 ,ug/ml for AGE-BSA, and 100 ug/ml for FFI-BSA, beyond which levels the response began to decline.
The results of the experiments described above indicated that cachectin/TNF was capable of upregulating AGE-receptor expression, possibly via a specific binding site on the macrophage/monocyte cell surface, therefore we tested for cachectin/TNF receptors on both cells. As shown in Fig. 7 , both mouse peritoneal macrophages (A), and human monocytes (B) bound human cachectin/TNF with saturable kinetics. Scatchard plot analysis of binding data indicated that the mouse macrophage has 1.5 X I03 receptors/cell±48 SEM, with a dissociation constant (Kd) of 0.32 nM, while freshly isolated normal human monocytes possessed 1.6 X 103 binding sites/ cell±25 SEM with a Kd of 0.48 nM.
To test the hypothesis that the AGE-mediated increase of AGE-receptor function is mediated by the released cachectin/ TNF (9) , which in turn interacted with its own surface receptors in an autocrine fashion to exert an effect on the AGE-receptor, human monocytes were preincubated for 48 h with either cachectin/TNF, FFI-BSA, or conditioned medium (prepared from human monocytes previously exposed to FFI-BSA for 48 h), in the presence and absence ofan anticachectin/TNF Advanced Glycosylation Endproducts-Receptor Upregulation 1817 specific monoclonal antibody (SW 18.1.1) (22) . This antibody has been shown to completely neutralize TNF biological activity, as measured by cachectin/TNF-mediated L929 cell cytotoxicity (22) , without affecting TNF-# (lymphotoxin) activity (unpublished data). The cells were then allowed to bind radiolabeled AGE-BSA for 2 h at 4VC. As can be seen in Fig. 6 , the presence ofthe monoclonal antibody inhibited the stimulatory effect ofcachectin/TNF, FFI-BSA, or conditioned medium on '251-AGE-BSA binding by 90%. The prevention of AGE-receptor upregulation by the monoclonal antibody added to the conditioned medium indicated that cachectin/TNF was the predominant factor involved in this process. In order to assess the ability of cachectin/TNF to induce similar upregulation of the AGE-receptor-mediated processes in vivo, we measured the in vivo survival ofred blood cells that had been modified by linking FFI onto their surfaces. Previous work (8) had shown that in mice these modified RBC have a shortened survival in the circulation compared with normal RBC. Red blood cells from donor rats were modified by FFI-HA or with PBS alone (8) , and after 51Cr-labeling were injected intravenously into recipient animals which were given rhTNF intraperitoneally twice daily for 7 d. Rats receiving cachectin/ TNF failed to gain body weight and displayed a 26% decline in hematocrit (data not shown), which is consistent with earlier reports (23) . As shown in Fig. 8 (27) . One mechanism that would allow these cells to selectively identify, internalize, and destroy senescent proteins is the high-affinity receptor specific for the AGE moiety (5) (6) (7) . In recent studies we have begun to examine the process by which removal of AGE-modified proteins might be coordinated with their replacement by newly synthesized material. We have found that in response to binding AGE-proteins, human monocytes synthesize and release the monokines cachectin/ TNF and IL-1 (9) . These proteins are known to have diverse biological effects (28) including growth factor-like (29) (30) (31) and angiogenic activities (32, 33) possibly involved in tissue growth and remodeling. The effectiveness ofthis repair process is also dependent on the efficient removal of altered proteins. We have therefore examined the ability ofphysiological mediators such as insulin (12) , and cachectin/TNF to regulate the rate of uptake and elimination of AGE-protein by macrophages. In this study cachectin/TNF induced a severalfold enhancement ofbinding, endocytosis'and degradation of AGE-modified albumin by both murine resident peritoneal macrophages and human blood monocytes in vitro, and it enhanced the rate of disappearance of AGE-modified erythrocytes in vivo. In contrast, IL-1 did not stimulate the AGE-receptor specific activity, although it did induce endocytosis and processing ofunmodified albumin by an apparently nonspecific mechanism. In addition, IFN-'y did not upregulate the AGE-receptor activity on murine macrophages on 'its own, despite its known macrophage activating properties (25) , and it did not influence the effects of human cachectin/TNF on murine macrophage AGE-receptors.
Circulating human monocytes were selected as the most accessible human macrophage equivalent to test the general clinical relevance of these observations. Nonstimulated human monocytes after either 2 or 7 d in culture have very similar numbers of AGE-specific binding sites to murine resident peritoneal macrophages (6) ; however, the affinity of the human monocyte AGE-receptor was shown to be 10-fold lower than its murine counterpart (6) , which may reflect nonprimed macrophage precursor state. IFN-'y was therefore used on human monocytes in an effort'to more closely mimic primed tissue macrophages from mice (34, 35) . Others (36) have previously shown that IFN-'y alone elicits no detectable secretion of cachectin/TNF, although it can increase TNF binding to various cell lines (37, 38) . In addition, we have reported its ability to augment monocyte production of cachectin/TNF and IL-1 in response to AGE-protein (9 (43, 44) , as was the number ofbinding sites ( 1,500 sites/cell) (45) .
From the studies presented above it seems plausible that the macrophage utilizes cachectin/TNF, induced by AGEprotein uptake (9) , in an autocrine manner to regulate the AGE-receptor function. TNF binds with a 1,000-fold higher affinity than AGE-BSA to the cells, therefore only a small amount bound to the TNF-receptor is necessary to influence AGE-receptor function. Similarly, other receptor functions have been shown to be modulated by hormones such as the downregulation of both Fc- (46) and AGE-receptor function (12) by insulin. Within 48 h of exposure to cachectin/TNF, macrophages undergo a modulation of their AGE-protein recognition capacity allowing them to promote the removal of AGE-proteins maximally. The specificity of cachectin/TNF action to induce increased AGE-receptor function is noted by its complete prevention by a monoclonal antibody that is specific for TNF-a and not TNF-,3 (22, and unpublished data) . Similarly the ability ofthis monoclonal antibody to inhibit the effect induced by conditioned media from macrophages previously incubated with AGE-ligands points to cachectin/TNF as the major mediator. This result is important since macrophages have the ability to produce a large number of mediators. The mechanism by which the monoclonal antibody neutralizes AGE-receptor upregulation has not yet been determined but, in view of the evidence for TNF receptors on these cells, one possibility is the inhibition of binding to the TNFreceptor; however other possibilities still exist.
Previous work has revealed that in vivo cachectin/TNF mimics many of the changes seen in chronic cachexia, including anemia (47) . A recent study on the mechanism of this anemia induced by cachectin/TNF has indicated a decreased rate of new red cell production, but more interestingly, a shortening of the lifespan of circulating red cells (23) . It is possible that this latter finding represents, in part, an upregulation of the AGE-receptor system resulting in an enhanced rate of removal specifically ofthose red cells with AGE-moieties formed on their surface proteins as a function ofage in circulation. We have previously demonstrated a decreased in vivo survival of AGE-modified RBC (8) , suggesting that these cells are selectively removed from the circulation. Our in vivo experiments of chronic cachectin/TNF administration causing acceleration of the disappearance rate of AGE-modified RBC in particular, support this notion. AGE-protein uptake by macrophages leads to synthesis and release of cachectin/TNF and IL-1 (9) . These mediators in turn, can prompt the release of additional mediators (28, 48), as well as proteolytic enzymes such as collagenase (49) , which collectively may provide the additional signals required for local tissue remodeling. The AGE-receptor is the first receptor known to recognize a protein modification that forms extensively in vivo as a function of time and glucose concentration.
Via this system macrophages can selectively promote the degradation of senescent macromolecules, and simultaneously initiate the process of tissue regeneration (1, 9) .
The demonstration of the upregulation of the AGE-receptor by cachectin/TNF contributes to the emerging picture of a physiological mechanism in which the macrophage AGE-receptor via cytokine induction could play a central role in the modulation of tissue protein turnover. In addition, the cachectin/TNF interaction with the AGE-receptor through an autocrine pathway may allow adaptation ofthe system to local requirements so that tissue homeostasis can be maintained. This finely coordinated macrophage system, although of unknown as yet capacity for senescent molecules in vivo, appears to function efficiently for several decades under physiologic conditions. Under significant burden, however, such as with aging or diabetes, where excessive tissue AGE accumulation is observed, an altered AGE-receptor expression ( 12) may reflect in part an inability of the macrophages to respond to the stimulatory effect of cachectin/TNF.
